Vaginal atrophy
- Authors: Glazunova A.V.1, Yureneva S.V.1, Ermakova E.I.1
-
Affiliations:
- Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- Issue: No 2 (2014)
- Pages: 21-26
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247130
- ID: 247130
Cite item
Open Access
Access granted
Abstract
Postmenopausal estrogen deficiency leads to vaginal atrophy in a number of women. The review gives recent data on the pathogenesis, clinical characteristics, and therapy of this condition.
Full Text
About the authors
Angelina Vladislavovna Glazunova
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: lianochkal85@yandex.ru
postgraduate of the gynecological endocrinology department
Svetlana Vladimirovna Yureneva
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: syureneva@gmail.com
MD
Elena Ivanovna Ermakova
Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: ermakova.health@mail.ru
PhD
References
- Sinha A., Ewies A.A. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013; 16(3): 305-12.
- Palacios S. Managing urogenital atrophy. Maturitas. 2009; 63(4): 315-8.
- Rosano G.M., Vitale C., Silvestri A., Fini M. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas. 2003; 46(Suppl.1): S17-29.
- Hextall A. Oestrogens and lower urinary tract function. Maturitas. 2000; 36(2): 83-92.
- Балан В.Е. Урогенитальные расстройства в климактерии (клиника, диагностика, заместительная гормонотерапия): Дис.. д-ра мед. наук. М.; 1998.
- Манухин И.Б., Тумилович Л.Г., Геворкян М.А. Клинические лекции по гинекологическойэндокринологии.М.:ГЭ0ТАР-Медиа;2006.320 с.
- Pickar J.H. Emerging therapies for postmenopausal vaginal atrophy. Maturitas. 2013; 75(1): 3-6.
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902.
- Castelo-Branco C., Cancelo M.J., Villero J., Nohales F., Juliá M.D. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005; 52(Suppl.1): S46-52.
- Griebling T.L., Liao Z., Smith P.G. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopal women. Menopause. 2012; 19: 630-5.
- Frank S.M., Ziegler C., Kokot-Kierepa M., Maamari R., Nappi R.E. Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. Menopause Int. 2012; Nov. 30.
- Kingsberg S.A., Krychman M.L. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J. Sex. Med. 2013; 10(6): 1567-70.
- Sturdee D.W., Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13: 509-22.
- Basaran M., Kosif R., Bayar U., Civelek B. Characteristics of external genitalia in pre-and postmenopausal women. Climacteric. 2008; 11: 416-21.
- Nyirjesy P. Postmenopausal vaginitis. Curr. Infect. Dis. Rep. 2007; 9: 480-4.
- Есефидзе Ж.Т. Клинико-патогенетические особенности вагинальной атрофии в постменопаузе: Автореф. дис.. канд. мед. наук. М.; 2002.
- DaSilvaLara L.A.,daSilva A.R.,Rosa-E-Silva J.C.,Chaud F.,Silva-de-Sá M.F., Meireles-E-Silva A.R., de Sá Rosa-E-Silva A.C. Menopause leading to increased vaginal wall thickness in women with genital prolapse: Impact on sexual response. J. Sex. Med. 2009; 6(11): 3097-110.
- Cheng X., Shen Z., Yin L., Lu S., Cui Y. ECRG2 regulates cell migration/ invasion through urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. J. Biol. Chem. 2009; 284: 30897-906.
- Dahn A., Saunders S., Hammond J., Carter D., Kirjavainen P., Anukam K., Reid G. Effect of bacterial vaginosis, Lactobacillus and Premarin estrogen replacement therapy on vaginal gene expression changes. Microbes Infect. 2008; 10(6): 620-7.
- Spear G.T., Kendrick S.R., Chen H.Y., Thomas T.T., Bahk M., Balderas R. et al. Multiplex immunoassay of lower genital tract mucosal fluid from women attending an urban STD clinic shows broadly increased IL1ß and lactoferrin. PLoS One. 2011; 6(5): e19560.
- Hummelen R., Macklaim J.M., Bisanz J.E., Hammond J.A., McMillan A., Vongsa R. et al. Vaginal microbiome and epithelial gene array in postmenopausal women with moderate to severe dryness. PLoS One. 2011; 6(11): e26602.
- Cotreau M.M., Chennathukuzhi V.M. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas. 2007; 58(4): 66-76.
- Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 2003; 2006; (4): CD001500.
- Сметник В.П. Эстрогены. М.: Практическая Медицина; 2012: 128-33.
- Pitkin J., Rees M.; British Menopause Society Council. Urogenital atrophy. Menopause Int. 2008; 14(3): 136-7.
- Labrie F., Archer D.F., Bouchard C., Fortier M., Cusan L., Gomez J.L. et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011; 14(2): 282-8.
- Bachmann G.A., Komi J.O.; The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010; 17(3): 480-6.
- Kagan R., Williams R.S., Pan K., Mirkin S., Pickar J.H. A randomized, placebo-and active-controlled trial of bazedoxifene/conjugated estrogens for treat-ment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010; 17(2): 281-9.
Supplementary files
